You are here

  • Home
  • Online First
  • Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease

Article Text

Article menu
Download PDFPDF
Short report
Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease
  1. Tatiana R Rosenblatt,
  2. Carolina A Chiou,
  3. Michael K Yoon,
  4. Nahyoung Grace Lee,
  5. Natalie Wolkow,
  6. Suzanne K Freitag
  1. Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA
  1. Correspondence to Dr Tatiana R Rosenblatt; trosenblatt{at}meei.harvard.edu

Abstract

Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab’s clinical effect since a given number of millimetres change can be of variable impact depending on patients’ degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2–40.5%) of their pre-treatment proptosis, or 3.3 mm (range 0.5–10.0 mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab’s clinical impact.

  • Orbit
  • Inflammation
  • Eye Lids
  • Treatment Medical
  • Cosmesis

https://doi.org/10.1136/bjo-2024-325527

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors TRR: data curation, methodology, formal analysis, visualization, writing – original draft, writing – review and editingCAC: data curation, methodology, writing – review and editingMKY: methodology, writing – review and editingNGL: methodology, writing – review and editingNW: methodology, writing – review and editingSKF: conceptualization, methodology, supervision, writing – review and editing.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests Competing Interests: TRR: None; CAC: None; MKY: Sling (Researcher), Viridian (Researcher); NGL: None; NW: None; SKF: ASPEN/Third Rock (Consultant), Horizon (Consultant), Immunovant (Consultant), Kriya (Consultant), Lassen (Consultant), Medtronic (Consultant), Poriferous (Consultant), Sling (Consultant), Viridan (Consultant), WL Gore (Consultant)

    • Provenance and peer review Commissioned; internally peer reviewed.